GenEmbryomics
Melbourne, Australia· Est.
GenEmbryomics delivers whole‑genome PGT to IVF embryos, enabling detection of chromosomal and genetic disorders before implantation.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
GenEmbryomics delivers whole‑genome PGT to IVF embryos, enabling detection of chromosomal and genetic disorders before implantation.
Reproductive HealthGenetic Disease Prevention
Technology Platform
Whole‑genome sequencing of embryonic DNA combined with a proprietary bioinformatics pipeline that detects aneuploidy, mosaicism, and pathogenic variants across >3,200 disease‑associated genes.
Opportunities
Rapid growth of IVF procedures worldwide and increasing demand for comprehensive embryo screening create a large market; regulatory clearance and reimbursement could unlock commercial revenue.
Risk Factors
Regulatory approval timelines, high cost of whole‑genome sequencing, and competition from established PGT providers could impede adoption.
Competitive Landscape
Competitors like Natera and Illumina offer targeted PGT panels; GenEmbryomics differentiates with a true whole‑genome approach that integrates mosaicism detection and extensive variant analysis.